Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH)

Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH

Session: Pulmonary hypertension: improving treatment in PAH
Session type: Oral Presentation
Number: 3419

Disease area: Pulmonary vascular diseases



Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Sitbon, R. N. Channick, M. Delcroix, H. A. Ghofrani, P. Jansa, F. O. Le Brun, S. Mehta, L. Perchenet, T. Pulido, L. J. Rubin, B. K. S. Sastry, G. Simonneau, R. Souza, A. Torbicki, N. Galiè (Le Kremlin-Bicêtre, France; Boston, San Diego, United States Of America; Leuven, Belgium; Giessen, Germany; Prague, Czech Republic; Allschwil, Switzerland; London, Canada; Mexico City, Mexico; Hyderabad, India; São Paulo, Brazil; Otwock, Poland; Bologna, Italy). Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH). Eur Respir J 2014; 44: Suppl. 58, 3419

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

• Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
• Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
• Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living